Evelo Biosciences, Inc. (EVLO) Stock Price & Analysis
Evelo Biosciences, Inc. (EVLO) closed at USD 0 on Wednesday, October 21, 2026, down 50.00% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 0; the Oct 21, 2026 session ranged USD 0–0 on volume of 133 shares. Market capitalization is $1,898, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, retrieved October 23, 2026 at 11:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EVLO.md
Key facts (EVLO)
- Analysts: None.
- Total return with dividends: 1Y -80.0% vs S&P 500 +14.9%; 5Y -100.0% vs S&P 500 +80.3%.
Analysts (EVLO)
Consensus None.
Total return (dividends reinvested) (EVLO)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -80.0% | -100.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -80.1% | -94.2% |
| Volatility (annualized) | 374.7% | 482.8% |
| Max drawdown | -80.0% (Oct 2025→Dec 2025) | -100.0% (Nov 2021→Jun 2024) |
EVLO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends Mar 2024) | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2023) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 23, 2026 at 11:23 UTC)
| Price | USD 0 |
|---|---|
| Change | ▼ 50.00% (down) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 133 shares |
| Market Cap | $1,898 |
| Exchange | PNK |
Technical Analysis (EVLO)
Nexqual's technical model rates EVLO "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 11:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.13 (oversold) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (EVLO)
Wall Street analysts rate EVLO "None", per Nexqual as of October 23, 2026 at 11:23 UTC.
| Consensus Rating | None |
|---|
Earnings (EVLO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -0.52 vs est -1.17 ▲ beat |
| 2023-06-30 | USD -3.07 vs est -3.81 ▲ beat |
| 2022-12-31 | USD -2.83 vs est -5.5 ▲ beat |
Source: Nexqual, October 23, 2026 at 11:23 UTC.
Financials & Fundamentals (EVLO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.48 |
| Total Cash | $17.26M |
| Total Debt | $33.95M |
Source: Nexqual, October 23, 2026 at 11:23 UTC.
Financial Health Score (EVLO)
Nexqual rates Evelo Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 11:23 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $17M cash vs $34M debt |
| Cash Flow | Weak — Operating cash flow -$74M (TTM) |
| Efficiency | Mixed — No data |
Ownership (EVLO)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 18.98M |
| Float | 18.90M |
| Short % of Float | +2.22% |
Source: Nexqual, October 23, 2026 at 11:23 UTC.
Leadership (EVLO)
Evelo Biosciences, Inc. is led by Craig R. Jalbert CIRA, President, Secretary, Principal Executive, Financial and Accounting Officer & Director, per Nexqual as of October 23, 2026 at 11:23 UTC.
| President, Secretary, Principal Executive, Financial and Accounting Officer & Director | Craig R. Jalbert CIRA |
|---|---|
| Senior Director & Immunology Clinical Lead | Douglas Maslin |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt